“As pioneers in cancer immunotherapy, Clasp is committed to extending and enhancing the lives of cancer patients worldwide,” stated Clasp CEO Robert Ross. “Our mission is to harness the power of the immune system to eradicate cancer with unparalleled precision, while minimizing the adverse effects commonly associated with traditional treatments.”
2 Biotechs Unveil Separate Fundings Totaling $325M : Reshaping Disease Management
Meanwhile, on the West Coast, Capstan Therapeutics, headquartered in San Diego, California, emerged with a $175 million Series B financing round. Spearheaded by RA Capital Management, this round saw the participation of heavyweight investors such as Forbion and Johnson & Johnson Innovation, alongside stalwarts like Bristol Myers Squibb and Eli Lilly and Co.
Capstan’s groundbreaking approach involves in vivo cell reprogramming through targeted RNA delivery using lipid nanoparticles. Their therapies offer hope for patients grappling with autoimmune disorders, cancers, fibrosis, and monogenic blood disorders.
